Where the Street stands
These are third-party analyst opinions from named firms, not advice, and not a prediction. Earnings land in 7 days, which usually moves targets. How we score this
19 firms currently rating it, weighted by track record.
The 18 firms with a track record here beat the S&P 43% of the time over 12 months.
Pro: see the crowd-vs-sharp split for MRKMerck trades at $124.40 with a consensus buy rating from 26 analysts, whose average price target of $134.04 implies 7.7% upside. JPMorgan, BMO Capital, and Guggenheim all maintained bullish ratings on July 13, while Morgan Stanley rates the stock Equal-Weight. The company carries a trailing P/E of 35.95 against forward P/E of 12.88, with 4.9% revenue growth and a 13.59% net margin; the stock trades near its 52-week high of $131.74 amid questions about Keytruda's patent cliff and competition from newer oncology drugs.
Generated from the data on this page; may contain errors. Analyst opinions belong to the named firms. Informational only, not investment advice.
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jul 13, 2026 | JPMorgan | ○ Maintained | |
| Jul 13, 2026 | BMO Capital | ○ Maintained |
Create a free account to unlock all analyst ratings, key stats, and news. No credit card, takes 30 seconds.
Sign up free